- India's one-horned rhino numbers charging ahead, govt says
- Rescuers comb muddy riverbanks after Japan floods kill seven
- Asian stocks boosted by US rate cut, China stimulus hope
- Sri Lanka's new leader says no magic solution to crisis
- Israel warns Lebanese as wave of strikes hits Hezbollah
- New Socceroos coach Popovic confident he can rescue World Cup campaign
- 'Put Austrians first': On a pub crawl with far-right voters
- Trial begins in Italy student murder case that opened eyes to femicide
- Family of murdered Sri Lanka editor seek justice from new president
- Austria's far right woos anti-vaxxers with fund for vaccine 'victims'
- Long wait for justice in India's backlogged courts
- Rohingya refugees detail worsening violence in Myanmar
- Rescuers comb muddy riverbanks after Japan floods kill six
- Sri Lankan leftist leader sworn in after landslide election win
- Indonesia, NZ deny Papua rebel claim 'bribe' paid for pilot release
- Swearing, shoeys and swift legs: Singapore GP talking points
- South Korea warns of 'decisive' action against trash balloons
- Football Australia names Tony Popovic as Socceroos coach
- Japan quake, flood victim attempts fresh start with wife's memory
- Japan quake, flood victim attemps fresh start with wife's memory
- Asian markets extend gains as focus turns to US inflation
- Six dead after floods in central Japan: media
- Australian golf prodigy suffers career-threatening eye injury
- Gaza hospital a symbol of the ruin of war
- October 7: how Israel's deadliest day unfolded
- Bibles, sneakers, silver coins: Trump's merch for sale
- Met Opera opens season with tech-heavy 'Grounded'
- Colombia's Inirida flower: from 'weed' to emblem for UN meeting
- Colombia rebel group imposes control in restive coca zone
- Rams fight back to upset 49ers, Cowboys lose again
- Sri Lankan leftist leader to take office after landslide election win
- 300-kilo WWI bomb removed in Belgrade
- Zelensky in US to explain war plan to Biden, Harris, Trump
- 'Atrocious' Sudan war pushing refugees further afield: UNHCR chief
- 'Convergence' growing on global plastics treaty: UN environment chief
- MLB White Sox fall to Padres to match one-season loss mark
- All-Australian Ripper squad captures LIV Golf team crown
- Barnier promises compromise from France's embattled new govt
- Zelensky arrives in US to explain war plan to Biden
- Barca rout Villarreal but Ter Stegen hurt, Atletico draw at Rayo
- Darnold shines for Vikings, Steelers and Eagles win
- Atletico held to draw at Rayo Vallecano
- Marseille stun Lyon with 95th-minute winner after early red card
- Gabbia ends AC Milan's derby pain with late winner against Inter
- Surging Ko claims LPGA Queen City crown in spectacular style
- 'Impossible': Alcaraz shoots down Federer comparisons after Laver Cup win
- Scholz's party beats far-right AfD in east German state vote
- Verstappen says 'silly' swearing row could hasten F1 exit
- Calls for Israel and Hezbollah to step back from the abyss
- Israel and Hezbollah urged to avoid 'catastrophe'
US approves gene therapy treatment for hemophilia
Pharmaceutical giant Pfizer has received US approval for a gene therapy against a form of hemophilia, a rare and inherited blood clotting disorder, the company said Friday.
Beqvez, which is given as a single intravenous infusion, was shown in a clinical trial of 45 people to be better at preventing bleeding among adults with moderate to severe hemophilia B, compared to regular infusions of a protein that promotes clotting, called protein factor IX (FIX).
The current standard of care is cumbersome, requiring infusions up to several times per week.
"Many people with hemophilia B struggle with the commitment and lifestyle disruption of regular FIX infusions, as well as spontaneous bleeding episodes, which can lead to painful joint damage and mobility issues," said Adam Cuker, director of the University of Pennsylvania's Comprehensive Hemophilia and Thrombosis Program, in a Pfizer statement.
"A one-time treatment with BEQVEZ has the potential to be transformative for appropriate patients by reducing both the medical and treatment burden over the long term."
The therapy was generally well tolerated but a common side effect was elevated liver enzymes, a sign of liver inflammation that wasn't accompanied by outward symptoms. Still, patients are advised to avoid alcohol for up to a year following their treatment, to prevent liver damage.
Patients will be followed up to gather more data for up to 15 years.
Pfizer's genetic therapy targets hemophilia B, the second most common form of the condition, which primarily affects males. More than 38,000 people worldwide live with hemophilia B, according to the World Federation of Hemophilia.
It works by infecting the body with a virus, modified to be harmless, which delivers a functional copy of the factor IX gene to liver cells, instructing them to produce the protein that promotes clotting that the patient otherwise lacks.
It received approval by Canada in January and is awaiting review by the European Medicines Agency.
Pfizer's statement did not mention a list price, which is often a limiting factor for gene therapy treatments. Recently approved sickle cell gene therapies run to $3 to $4 million before insurance.
O.Johnson--AMWN